{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:43:53Z","timestamp":1760147033878,"version":"build-2065373602"},"reference-count":32,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900601","LR2019073","RC200438"],"award-info":[{"award-number":["81900601","LR2019073","RC200438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Innovation Team and Innovative Talent Support Program of Liaoning Province","award":["81900601","LR2019073","RC200438"],"award-info":[{"award-number":["81900601","LR2019073","RC200438"]}]},{"name":"Young and Middle-Aged Science and Technology Innovation Talent Program","award":["81900601","LR2019073","RC200438"],"award-info":[{"award-number":["81900601","LR2019073","RC200438"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Familial gastrointestinal stromal tumor (GIST) is a rare autosomal dominant genetic disorder with only a few affected families reported to date. Here, we report a case of familial GISTs harboring a novel germline mutation within exon 18 of KIT. A 58-year-old male patient presented with gastric subepithelial lesions accompanied by cutaneous hyperpigmentation, which were subsequently diagnosed as multinodular GISTs. Endoscopic surgery was initially conducted to remove the larger lesions, and pathological examinations were then conducted for the diagnosis of GISTs. Family history revealed that some other family members had similar cutaneous pigmentations. Whole-exome sequencing was used to search for potential driver mutations, and Sanger sequencing was used for mutation validation. A novel primary driver mutation of KIT (c.G2485C, p.A829P) was detected in these hereditary GISTs, which has been reported in some targeted chemotherapy-resistant GISTs. Cell models were subsequently established for the rapid screening of candidate drugs and exploring potential mechanisms. This mutation could lead to cell proliferation and imatinib resistance by ligand-independent activation of KIT; however, ripretinib administration was identified as an applicable targeted therapy for this mutation. The mutation activated the JAK\/STAT3 and MAPK\/ERK pathways, which could be inhibited by ripretinib administration. To the best of our knowledge, this is the first report of the KIT-A829P mutation in familial GISTs, complementing the pathogenesis of familial GISTs and providing valuable information for the precision treatment of this disease.<\/jats:p>","DOI":"10.3390\/ijms24010830","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T04:08:07Z","timestamp":1672805287000},"page":"830","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chinese Pedigree with Hereditary Gastrointestinal Stromal Tumors: A Case Report and Literature Review"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-2033","authenticated-orcid":false,"given":"Qichao","family":"Ge","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang 110004, China"},{"name":"Innovative Research Center for Integrated Cancer Omics, Shengjing Hospital of China Medical University, Shenyang 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang 110004, China"},{"name":"Innovative Research Center for Integrated Cancer Omics, Shengjing Hospital of China Medical University, Shenyang 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangwei","family":"Sun","sequence":"additional","affiliation":[{"name":"Innovative Engineering Technology Research Center for Cell Therapy, Shengjing Hospital of China Medical University, Shenyang 110022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-6359","authenticated-orcid":false,"given":"Jintao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang 110004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ctrv.2016.11.011","article-title":"GEIS Guidelines for Gastrointestinal Sarcomas (GIST)","volume":"55","author":"Poveda","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","article-title":"The Management of Metastatic GIST: Current Standard and Investigational Therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","article-title":"Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade","volume":"26","author":"Serrano","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal Stromal Tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10120-020-01055-7","article-title":"Multiple Gastrointestinal Stromal Tumors Caused by a Novel Germline KIT Gene Mutation (Asp820Gly): A Case Report and Literature Review","volume":"23","author":"Arima","year":"2020","journal-title":"Gastric Cancer"},{"doi-asserted-by":"crossref","unstructured":"Fornasarig, M., Gasparotto, D., Foltran, L., Campigotto, M., Lombardi, S., Del Savio, E., Buonadonna, A., Puglisi, F., Sulfaro, S., and Canzonieri, V. (2020). A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity. J. Pers. Med., 10.","key":"ref_6","DOI":"10.3390\/jpm10040234"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/ced.13757","article-title":"Cutaneous Hyperpigmentation and Familial Gastrointestinal Stromal Tumour Associated with KIT Mutation","volume":"44","author":"Wali","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_8","first-page":"1766","article-title":"Multiple Gastrointestinal Stromal Tumors with Exon 11 Mutation of the C-KIT Gene in a Young Male without Family History","volume":"13","author":"Zhou","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/PAS.0b013e31827bc071","article-title":"A Novel Germline KIT Mutation (p.L576P) in a Family Presenting with Juvenile Onset of Multiple Gastrointestinal Stromal Tumors, Skin Hyperpigmentations, and Esophageal Stenosis","volume":"37","author":"Neuhann","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13578-016-0120-8","article-title":"Germline Mutations of KIT in Gastrointestinal Stromal Tumor (GIST) and Mastocytosis","volume":"6","author":"Ke","year":"2016","journal-title":"Cell Biosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/pde.13952","article-title":"Novel KIT Mutation Presenting as Marked Lentiginosis","volume":"36","author":"Tran","year":"2019","journal-title":"Pediatr. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/bjd.16895","article-title":"Autosomal Dominant Progressive Hyperpigmentation and Lentigines in a Japanese Pedigree Due to a Missense Mutation near the C-Terminus of KIT","volume":"179","author":"Takeichi","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"847382","DOI":"10.3389\/fmed.2022.847382","article-title":"Case Report: A Missense Mutation of KIT in Hyperpigmentation and Lentigines Unassociated With Systemic Disorders: Report of a Chinese Pedigree and a Literature Review","volume":"9","author":"Yang","year":"2022","journal-title":"Front. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4103\/EUS-D-21-00035","article-title":"Efficacy of the Franseen Needle for Diagnosing Gastrointestinal Submucosal Lesions Including Small Tumors","volume":"10","author":"Nagai","year":"2021","journal-title":"Endosc. Ultrasound"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4103\/eus.eus_29_20","article-title":"Evolution and a Promising Role of EUS-FNA in Gene and Future Analyses","volume":"9","author":"Kuwatani","year":"2020","journal-title":"Endosc. Ultrasound"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-018-0414-1","article-title":"KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development","volume":"20","author":"Meng","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem Cell Factor Receptor\/c-Kit: From Basic Science to Clinical Implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol. Rev."},{"doi-asserted-by":"crossref","unstructured":"Guo, J., Ge, Q., Yang, F., Wang, S., Ge, N., Liu, X., Shi, J., Fusaroli, P., Liu, Y., and Sun, S. (2022). Small Gastric Stromal Tumors: An Underestimated Risk. Cancers, 14.","key":"ref_18","DOI":"10.2139\/ssrn.4219099"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/gast.2001.20880","article-title":"Familial Gastrointestinal Stromal Tumor with Hyperpigmentation: Association with a Germline Mutation of the c-Kit Gene","volume":"120","author":"Maeyama","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/1209","article-title":"Familial Gastrointestinal Stromal Tumours with Germline Mutation of the KIT Gene","volume":"19","author":"Nishida","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/pcmr.12107","article-title":"Secondary C-Kit Mutations Confer Acquired Resistance to RTK Inhibitors in c-Kit Mutant Melanoma Cells","volume":"26","author":"Todd","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT Kinase Mutants Show Unique Mechanisms of Drug Resistance to Imatinib and Sunitinib in Gastrointestinal Stromal Tumor Patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s11864-022-00996-8","article-title":"Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges","volume":"23","author":"Huang","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and Safety of Regorafenib for Advanced Gastrointestinal Stromal Tumours after Failure of Imatinib and Sunitinib (GRID): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and Safety of Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumour after Failure of Imatinib: A Randomised Controlled Trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","article-title":"Efficacy and Safety of Regorafenib in Patients With Metastatic and\/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial","volume":"30","author":"George","year":"2012","journal-title":"JCO"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumours (INVICTUS): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.2217\/fon-2019-0633","article-title":"Intrigue: Phase III Study of Ripretinib versus Sunitinib in Advanced Gastrointestinal Stromal Tumor after Imatinib","volume":"16","author":"Nemunaitis","year":"2020","journal-title":"Future Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2217\/fon-2022-0226","article-title":"Ripretinib in Advanced Gastrointestinal Stromal Tumors: An Overview of Current Evidence and Drug Approval","volume":"18","author":"Goggin","year":"2022","journal-title":"Future Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","article-title":"Ripretinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.V126.23.568.568","article-title":"Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations","volume":"126","author":"Evans","year":"2015","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/830\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:57:18Z","timestamp":1760119038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24010830"],"URL":"https:\/\/doi.org\/10.3390\/ijms24010830","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}